Rimonabant: From RIO to Ban

Abstract

Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century. The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside improvements in numerous other elements of the metabolic syndrome. However, the drug was quickly withdrawn due to the emergence of significant side effects—notably severe mood disorders. This paper provides a brief overview of the Rimonabant story and places the recent spate of FDA rejections of other centrally acting weight loss drugs entering Phase 3 trials in this context.

Cited by papers we hold 5

• Signaling pathways in obesity: mechanisms and therapeutic interventions · 2022
  Corrected
• The Cannabinoid Receptor 1 Reverse Agonist AM251 Ameliorates Radiation-Induced Cognitive Decrements · 2021
  Not checked
• A Systematic Review of the European Rapid Alert System for Food and Feed: Tendencies in Illegal Food Supplements for Weight Loss · 2021
  Not checked
• ω-3 and ω-6 Polyunsaturated Fatty Acids, Obesity and Cancer · 2020
  No notice
• Emerging Evidence for Cannabis' Role in Opioid Use Disorder · 2018
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.